Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 5/20 | 0.46 |
| ▸ | RAB9A | P51151 | 5/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.46 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.45 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.45 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.45 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.45 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.45 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.43 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.43 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.43 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2295665 | 0.93 | PSEN1 (0.45) | KMT2ANPC1RAB9ASMN1; SMN2PSEN1 | |
| SCHEMBL2291392 | 0.92 | KMT2A (0.51) | KMT2ANPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL5305129 | 0.91 | NPC1 (0.49) | KMT2ANPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL2291248 | 0.89 | USP2 (0.51) | KMT2ANPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL5295744 | 0.86 | BCHE (0.46) | KMT2ANPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL2295330 | 0.86 | ALDH1A1 (0.53) | KMT2ANPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL2297135 | 0.86 | KMT2A (0.46) | KMT2ANPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL2297533 | 0.85 | ITGB3 (0.50) | KMT2ANPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL2295280 | 0.85 | KMT2A (0.50) | KMT2ANPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL2291378 | 0.85 | NPC1 (0.62) | KMT2ANPC1RAB9ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003806-B2 | Integrin antagonists useful as anticancer agents | OSI Pharmaceuticals, LLC (US) | 2011-08-23 | — | — | US | claimed |
| US-20060116383-A1 | Integrin antagonists useful as anticancer agents | ALCATEL LUCENT (FR) | 2006-06-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116383-A1 | Integrin antagonists useful as anticancer agents | ITGB5, ITGA5, ITGB1 | KMT2A 3680/4885NPC1 2770/4885RAB9A 1893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.